肝癌靶向治疗中手足皮肤反应研究进展

肝癌电子杂志 ›› 2024, Vol. 11 ›› Issue (4): 54-59.

肝癌靶向治疗中手足皮肤反应研究进展

宁艳婷¹, 夏娟², 吴舒^1,3, 张琦⁴, 李晓青⁴, 车旭⁴, 占正寅^4,*

1.国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院深圳医院护理部,深圳 518116;
2.国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院深圳医院重症医学科,深圳 518116;
3.南华大学护理学院,衡阳 421001;
4.国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院深圳医院肝胆外科,深圳 518116

收稿日期:2024-06-03 出版日期:2024-12-30 发布日期:2025-02-25
通讯作者: ^*占正寅,E-mail: zhanzhengyin@cicams-sz.org.cn
基金资助:
深圳市“医疗卫生三名工程”项目资助（SZSM202011010）; 2024年深圳市卫生经济学会项目（2024160）; 广东省护士协会循证护理实践专项计划项目（gdnurse2024xz10）; 中国医学科学院肿瘤医院深圳医院院内科研课题资助（E010424005）

Research progress on hand-foot skin reaction in targeted therapy for hepatocellular carcinoma

Ning Yanting¹, Xia Juan², Wu Shu^1,3, Zhang Qi⁴, Li Xiaoqing⁴, Che Xu⁴, Zhan Zhengyin^4,*

1. National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital &Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Nursing Department, Shenzhen 518116, China;
2. National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital &Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College ICU, Shenzhen 518116, China;
3. School of Nursing, University of South China, Hengyang 421001, China;
4. National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Hepatobiliary Surgery Department, Shenzhen 518116, China

Received:2024-06-03 Online:2024-12-30 Published:2025-02-25
Contact: ^*Zhan Zhengyin,E-mail: zhanzhengyin@cicams-sz.org.cn

摘要/Abstract

摘要： 靶向药物作为肝癌治疗的重要手段,显著提高了肝癌患者的总体生存率。然而在治疗过程中不可避免地出现一些副作用,其中手足皮肤反应（HFSR）是常见的不良反应之一,不仅影响患者的生活质量,还可能迫使患者减少药物剂量或中断治疗,从而影响治疗效果。本文通过综合分析国内外关于靶向药物相关HFSR研究现状,探讨其发病机制、临床表现、分级标准,对比化疗相关手足综合征的差异。此外,本文还着重讨论了HFSR的预防与护理策略、健康教育、中西医治疗等,旨在减轻患者的症状,改善其生活质量,提高其治疗依从性;同时对肝癌靶向治疗中HFSR现存的问题以及未来发展趋势进行总结,以期为临床医生和护理工作者提供全面的参考依据,为肝癌靶向药物治疗相关的HFSR的预防和管理提供依据。

关键词: 肝癌, 靶向治疗, 手足皮肤反应, 干预措施

Abstract: Targeted drugs, as an important means in the treatment of liver cancer, have significantly improved the overall survival rate of liver cancer patients. However, some side effects inevitably occur during treatment. Hand-foot skin reaction is one of the common adverse reactions, which not only affects the patient's quality of life, but may also force the patient to reduce the dosage of the drug or interrupt treatment. , thus affecting the therapeutic effect. This article comprehensively analyzes the current research status of hand-foot skin reactions related to targeted drugs at home and abroad, discusses its pathogenesis, clinical manifestations, and grading standards, and compares the differences in chemotherapy-related hand-foot syndrome. In addition, this article also focuses on the prevention and care strategies, health education, traditional Chinese and Western medicine treatments for hand-foot skin reactions, etc, aiming to reduce patients' symptoms, improve their quality of life, and improve their treatment compliance. At the same time, the existing problems and future development trends of hand-foot skin reactions in liver cancer targeted therapy are summarized, with a view to providing a comprehensive reference basis for clinicians and nursing workers, and for the prevention and management of hand-foot skin reactions related to liver cancer targeted drug treatment.

Key words: Hepatocellular carcinoma, Targeted therapy, Hand-foot skin reactions, Intervention measure

宁艳婷, 夏娟, 吴舒, 张琦, 李晓青, 车旭, 占正寅. 肝癌靶向治疗中手足皮肤反应研究进展[J]. 肝癌电子杂志, 2024, 11(4): 54-59.

Ning Yanting, Xia Juan, Wu Shu, Zhang Qi, Li Xiaoqing, Che Xu, Zhan Zhengyin. Research progress on hand-foot skin reaction in targeted therapy for hepatocellular carcinoma[J]. Electronic Journal of Liver Tumor, 2024, 11(4): 54-59.

参考文献

[1] RUMGAY H, ARNOLD M, FERLAY J, et al.Global burden of primary liver cancer in 2020 and predictions to 2040[J]. J Hepatol, 2022, 77(6): 1598-1606.
[2] 中国医学科学院北京协和医学院肿瘤医院消化道肿瘤多学科协作组,中国医疗保健国际交流促进会肝脏肿瘤分会,中国医疗保健国际交流促进会国际教育培训分会,等. 肝癌患者常见药物治疗相关不良反应互联网管理专家指导意见[J/CD]. 肝癌电子杂志,2021,8(2):16-22.
[3] LIN S M, LU S N, CHEN P T, et al.HATT: a phase Ⅳ, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma[J]. Hepatol Int, 2017 11(2): 199-208.
[4] CHANPRAPAPH K, RUTNIN S, VACHIRAMON V.Multikinase inhibitor-induced hand-foot skin reaction: a review of clinical presentation, pathogenesis, and management[J]. Am J Clin Dermatol, 2016, 17(4): 387-402.
[5] ZUEHLKE R L.Erythematous eruption of the palms and soles associated with mitotane therapy[J]. Dermatologica, 1974, 148(2): 90-92.
[6] Burgdorf WH, Gilmore WA, Ganick RG.Peculiar acral erythema secondary to high-dose chemotherapy for acute myelogenous leukemia. Ann Intern Med. 1982;97(1):61-2.
[7] 李萌,刘艳,张燕. 索拉非尼治疗晚期肾癌不良反应的观察及护理[J]. 护理研究,2008,22(1):69-71.
[8] DEGEN A, ALTER M, SCHENCK F, et al.The hand‐foot‐syndrome associated with medical tumor therapy-classification and management[J]. JDDGt, 2010, 8(9): 652-661.
[9] GOMEZ P, LACOUTURE M E.Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer[J]. Oncologist, 2011, 16(11): 1508-1519.
[10] CHANPRAPAPH K, RUTNIN S, VACHIRAMON V.Multikinase inhibitor-induced hand-foot skin reaction: a review of clinical presentation, pathogenesis, and management[J]. Am J Clin Dermatol, 2016, 17(4): 387-402.
[11] KOMATSU H, YAGASAKI K, HIRATA K,et al.Unmet needs of cancer patients with chemotherapy-related hand-foot syndrome and targeted therapy-related hand-foot skin reaction: a qualitative study[J]. Euro J Oncol Nurs, 2019, 38: 65-69.
[12] OGASAWARA S, KANAI F, OBI S, et al.Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma[J]. Hepatol Int, 2011, 5(3): 850-856.
[13] TAKAYASU K, ARII S, IKAI I, et al.Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients[J]. Gastroenterology, 2006, 131(2): 461-469.
[14] DAIICHI SANKYO, INC. A phase 3, randomized, double-blind study of tivantinib (ARQ 197) in subjects with MET diagnostic-high inoperable hepatocellular carcinoma treated with one prior systemic therapy[DB/OL].(2021-04-06)[2024-05-22]. https://clinicaltrials.gov/study/NCT01755767.
[15] OBA T, CHINO T, SOMA A, et al.Comparative efficacy and safety of tyrosine kinase inhibitors for thyroid cancer: a systematic review and meta-analysis[J]. Endocrine J, 2020, 67(12): 1215-1226.
[16] SATO-SANO M, CURY-MARTINS J, MACARENCO R, et al.Perforating dermatosis associated with multikinase inhibitors: report of two cases, including one associated with lenvatinib[J]. JDDG, 2018, 16(12): 1486-1489.
[17] ZHAO Y, LIU W, ZHENG L, Et al. Efficacy and safety of regorafenib as second-line treatment for patients with hepatocellular carcinoma and macrovascular invasion and(or) extrahepatic metastasis[J]. J Gastrointest Oncol, 2023, 14(6): 2536-2548.
[18] YANG S. Real-world effectiveness of regorafenib in the treatment of patients with hepatocellular carcinoma-a retrospective study[DB/OL].(2022-04-05)[2024-05-22]. https://clinicaltrials.gov/study/NCT05024539.
[19] 周晨,刘家成,石钦,等. 肝癌分子靶向药物及免疫抑制剂治疗的研究现状及进展[J/CD]. 中华介入放射学电子杂志,2019,7(3):243-250.
[20] KOBAYASHI K, KAWAKAMI K, YOKOKAWA T, et al.Association of hand-foot skin reaction with regorafenib efficacy in the treatment of metastatic colorectal cancer[J]. Oncology, 2019, 96(4): 200-206.
[21] NONOMIYA Y, YOKOKAWA T, KAWAKAMI K, et al.Regorafenib-induced hand-foot skin reaction is more severe on the feet than on the hands[J]. Oncol Res, 2019, 27(5): 551-556.
[22] BRUIX J, QIN S, MERLE P, et al.Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2017, 389(10064): 56-66.
[23] 吴舒,佘清,路虹. 肝癌患者口服甲磺酸仑伐替尼不良反应护理[J/CD]. 肝癌电子杂志,2021,8(1):58-60.
[24] YOSHINO T, KOMATSU Y, YAMADA Y, et al.Randomized phase Ⅲ trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations[J]. Investig New Drugs, 2015, 33(3): 740-750.
[25] 李苗,朱映霞,段相会. 卡瑞利珠单抗联合甲磺酸阿帕替尼、替吉奥治疗中晚期原发性肝癌的临床观察[J]. 中国医药指南,2023,21(22): 22-25.
[26] SAIF MW, SANDOVAL A.Atypical hand-and-foot syndrome in an African American patient treated with capecitabine with normal DPD activity: is there an ethnic disparity?[J]. Cutan Ocul Toxicol, 2008, 27(4): 311-315.
[27] WILLIAMS LA, GINEX PK, EBANKS GL JR, et al.ONS GuidelinesTM for cancer treatment-related skin toxicity[J]. Oncol Nurs Forum, 2020, 47(5): 539-556.
[28] MAHON SM, CARR E.Skin toxicities: common side effect[J]. Clin J Oncol Nurs, 2021, 25(6): 32.
[29] 张方圆,吕苏梅,杨玄,等. 中国癌症症状管理实践指南—皮肤反应[J]. 护士进修杂志,2019,34(22):2017-2024.
[30] LACOUTURE M E.Insights into the pathophysiology and management of dermatologic toxicities to EGFR-targeted therapies in colorectal cancer[J]. Cancer Nurs, 2007, 30(4 Suppl 1): s17-s26.
[31] CHEN J, WANG Z.How to conduct integrated pharmaceutical care for patients with hand-foot syndrome associated with chemotherapeutic agents and targeted drugs[J]. J Oncol Pharm Pract, 2021, 27(4): 919-929.
[32] MURUGAN K, OSTWAL V, CARVALHO M D, et al.Self-identification and management of hand-foot syndrome (HFS): effect of a structured teaching program on patients receiving capecitabine-based chemotherapy for colon cancer[J]. Support Care Cancer, 2016, 24(6): 2575-2581.
[33] DING J, FARAH MH, NAYFEH T, et al.Targeted therapy-and chemotherapy-associated skin toxicities: systematic review and Meta-analysis[J]. Oncol Nurs Forum, 2020, 47(5): 149-160.
[34] SZÉKELY H, TÓTH LM, RANCZ A, et al. Anti-tumor necrosis factor alpha versus corticosteroids: a threefold difference in the occurence of venous thromboembolism in inflammatory bowel disease-a systematic review and Meta-analysis[J]. J Crohns Colitis, 2024, 18(5): 773-783.
[35] WEST D. Four-arm study to evaluate urea 40% cream, fluocinonide 0.05% cream, tazarotene 0.1% cream,an emollient cream for the treatment of hand-foot skin reaction related to the use of multi-targeted tyrosine kinase inhibitor sorafenib[DB/OL].(2013-06-05)[2024-05-22]. https://clinicaltrials.gov/study/NCT00667589.
[36] LIEN R Y, TUNG H H, WU S L, et al.Validation of the prophylactic efficacy of urea‐based creams on sorafenib‐induced hand‐foot skin reaction in patients with advanced hepatocellular carcinoma: a randomised experiment study[J]. Cancer Rep, 2022, 5(7): e1532.
[37] CHARALAMBOUS D A. A double blind placebo control randomised trial to test the effectiveness of vitamin B6 in hand foot syndrome[DB/OL].(2018-08-07)[2024-05-22]. https://clinicaltrials.gov/study/NCT02625415.
[38] 中国医疗保健国际交流促进会肝脏肿瘤学分会,中国医疗保健国际交流促进会免疫学分会,《靶免联合局部治疗中晚期肝细胞癌中国专家共识》协作组. 靶向免疫联合局部治疗中晚期肝细胞癌中国专家共识[J/CD]. 肝癌电子杂志,2023,10(3):1-11.
[39] 邬明歆,李小江,牟睿宇. 阿帕替尼所致手足综合征的中医辨证阶段治疗[J]. 中医药导报,2019,25(9):39-41.
[40] LEE Y C. The efficacy of acupuncture and laser acupuncture in treating chemotherapy or target therapy-induced hand-foot syndrome[DB/OL].(2023-07-18)[2024-05-22]. https://clinicaltrials.gov/study/NCT05949307.
[41] 许莲琴,毛燕君,江旭,等. 护理干预对肝癌病人口服索拉非尼致手足综合征的影响[J]. 护理研究,2012,26(12):1111-1112.
[42] NAGANUMA A, HOSHINO T, OHNO N, et al.β-hydroxy-β-methyl butyrate/l-arginine/l-glutamine supplementation for preventing hand-foot skin reaction in sorafenib for advanced hepatocellular carcinoma[J]. In Vivo, 2019, 33(1):155-161.
[43] HUNG C T, CHIANG C P, WU B Y.Sorafenib-induced psoriasis and hand-foot skin reaction responded dramatically to systemic narrowband ultraviolet B phototherapy[J]. J Dermatol, 2012, 39(12): 1076-1077.
[44] 吴舒,张培培,占正寅,等.肝癌靶向药物相关手足皮肤反应的护理研究进展[J]. 护理学报,2024,31((13):45-49.